RSM logo
Annals of Clinical Biochemistry

Home Current issue Browse archive Alerts About the journal Feedback
 
This version was published on 1 November 2008
Ann Clin Biochem 2008;45:560-566
doi:10.1258/acb.2008.008033
© 2008 Association for Clinical Biochemistry

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stronge, R L
Right arrow Articles by Ardill, J E S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours

R L Stronge1, G B Turner2, B T Johnston3, D R McCance3, A McGinty4, C C Patterson5 and J E S Ardill3


1 St George's Hospital Medical School, University of London; 2 Altnagelvin Hospital, Londonderry; 3 Neuroendocrine Tumour Group, Royal Victoria Hospital; 4 School of Medicine; 5 Medical Statistics, Queen's University, Belfast, UK


Figure 1
View larger version (15K):
[in this window]
[in a new window]

  		Figure 1 Change in circulating pancreastatin pre- to during-treatment with somatostatin analogues (SST)

 

Figure 2
View larger version (10K):
[in this window]
[in a new window]

  		Figure 2 Kaplan-Meier plot of cumulative survival against the change in pancreastatin (during-treatment:pre-treatment pancreastatin ratio). Solid line denotes reduced or no change; dashed line denotes 1.5-fold to five-fold increase; dotted line denotes >five-fold increase: (blot denotes censored). {chi}2 = 24.364 (P < 0.001)

 

Figure 3
View larger version (10K):
[in this window]
[in a new window]

  		Figure 3 Kaplan-Meier plot of cumulative survival against primary tumour site. Solid line denotes midgut carcinoid tumours; dashed line denotes broncho-pulmonary tumours and dotted line denotes pancreatic tumours (blot = censored). {chi}2 = 10.36 (P = 0.006)

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



MDU Exam Doctor

 RSM Books - Beyond Thalidomide RSM Press eJournals Collection 2010